Protalix BioTherapeutics, PLX , announced today that it has entered into a
Clinical Development Agreement with Pfizer Inc. under which Protalix will
continue to manage, administer and sponsor current, ongoing clinical trials
relating to ELELYSO^TM (taliglucerase alfa). Protalix is currently sponsoring
adult and pediatric extension studies of ELELYSO. New clinical trials for
ELELYSO will be conducted and sponsored by Pfizer.
Under the terms of the agreement, Protalix is eligible to receive a milestone
payment of $8.3 million upon the achievement of certain near-term clinical
development milestones.
This agreement helps to maintain the continuity of the ongoing clinical trials
for Gaucher patients and physicians and reinforces the companies' mutual
commitment to the Gaucher community.
On November 30, 2009, Pfizer and Protalix entered into an agreement to develop
and commercialize taliglucerase alfa, an enzyme replacement therapy for the
treatment of Gaucher disease. Under the terms of the agreement, Pfizer
received exclusive worldwide licensing rights for the commercialization of
taliglucerase alfa, while Protalix retained the exclusive commercialization
rights in Israel.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in